

Korea's Rznomics joins Lilly Gateway Labs in US to accelerate RNA Therapeutics

August 24, 2026 | News

Active collaboration with the global biotech ecosystem



South Korea based Rznomics Inc, a biopharmaceutical company specialising in the development of RNA-based gene therapies, has announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California, US.

Lilly Gateway Labs is a best-in-class innovation hub designed to empower biotechnology companies to advance groundbreaking science by providing access to wet lab facilities and opportunities to engage with Lilly scientists and executives. Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.

Through its entry into Lilly Gateway Labs, Rznomics plans to accelerate candidate discovery and development across its target gene database bank comprising over 200 disease targets, while simultaneously driving long-term efforts to establish global clinical infrastructure for its lead pipelines, expand global strategic partnerships, and recruit top-tier R&D researchers in the US.